CD274 and neoplasm: In a randomized phase 2 and 3 trial (KEYNOTE-010) with 1034 NSCLC patients who were previously treated with chemotherapy and were PD-L1–positive in tumor cells based on immunohistochemical analysis (≥1%) [21] (Table 1), patients were randomly assigned to three arms: pembrolizumab at 2 mg/kg, pembrolizumab at 10 mg/kg, and docetaxel at 75 mg/m2.